Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
For most CLL (chronic lymphocytic leukemia) patients who have received six years of continuous ibrutinib treatment, the levels of residual disease decrease or remain stable for the subsequent 6-12 months after stopping ibrutinib.
With a four-year follow-up, fixed-duration I + V continues to provide deep, durable remissions with clinically meaningful progression-free survival (PFS) and time off treatment, including in patients with high-risk disease features.
In the setting of the COVID-19 pandemic, progression-free survival with first-line ibrutinib + venetoclax + obinutuzumab treatment was not superior to ibrutinib + obinutuzumab for older patients with previously untreated CLL. Follow-up remains ongoing, and many patients in the ibrutinib + venetoclax + obinutuzumab arm achieved undetectable measurable residual disease.
More research is presented again, proving that targeted therapies, in this case, ibrutinib, are significantly superior to chemoimmunotherapy (CIT) in front-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL).
This real-world study found that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib were more likely to need to change therapies or add an additional therapy compared with patients treated with ibrutinib.
Patients with acalabrutinib had lower discontinuation rates and a prolonged time to discontinuation compared to pts treated with ibrutinib.
The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)
I am grateful to Nathan Vardi for illuminating this incredible story’s corners, and I highly recommend his book.
These results offer some encouraging news regarding cancer care for adults with predominantly African ancestry
One click to our most popular content.
